Bayer Bets on Barcelona with a New R&D Area in Health

Bayer is increasing its commitment to Spain. The pharmaceutical multinational has announced that it will incorporate a new R&D area in health and agriculture through its expertise hub. The research centre will be integrated into its headquarters in Barcelona.

The project brings together 82 professionals who will provide services in the areas of global research and development for the advancement of innovation in health and agriculture. The team is made up of scientific profiles who will provide support in clinical trials and in the management of the safety and quality process of medicines.

“The new hub confirms our strength in developing innovation for the whole world and completes our contribution of value from Spain,” said Jordi Sánchez, CEO of Bayer Spain in a statement.

The pharmaceutical company claims that in the last year they have invested more than 130 million euros, while on a global scale, investment in R&D was 5.8 billion euros.

Bayer has had an innovation hub in Barcelona for more than two decades

The Bayer Service Center has been operational since 2001 and is located in Sant Joan Despí (Barcelona). Since its inception, the center has been incorporating new areas of development, especially in artificial intelligence to improve efficiency, traceability and agility in processes.

In the past five years, the number of employees at the Bayer hub has increased by 75% to 822, mainly in scientific fields. The Barcelona centre serves eleven countries in Europe and the Middle East.

Bayer closed the first nine months of the year with global sales of 34.877 billion euros, 2.5% less than in the same period of the previous year. The group’s losses increased by 48.2% between January and September, reaching 2.217 billion euros.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us